Clinical trials
Phase 1 Dermatitis, Atopic trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
80 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 10 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 7 |
| 2023 | 7 |
| 2024 | 6 |
| 2025 | 11 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 56 |
| Terminated | 9 |
| Recruiting | 8 |
| Withdrawn | 3 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 9 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 6 |
| Amgen | 3 |
| Eli Lilly and Company | 3 |
| Incyte Corporation | 3 |
| LEO Pharma | 3 |
| Regeneron Pharmaceuticals | 3 |
| AbbVie | 2 |
| Arcutis Biotherapeutics, Inc. | 2 |
| Asana BioSciences | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dermatitis, Atopic | 80 |
| Eczema | 16 |
| Dermatitis | 5 |
| Psoriasis | 4 |
| Pruritus | 3 |
| Rhinitis, Allergic | 2 |
| Conjunctivitis, Allergic | 1 |
| Epidermolysis Bullosa | 1 |
| Food Hypersensitivity | 1 |
| Hidradenitis Suppurativa | 1 |
Trials
Showing 1 to 25 of 80. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.